US2008279926A1PendingUtilityA1

Vaccine Compositions Comprising a Saponin Adjuvant

50
Assignee: VANDEPAPELIERE PIERREPriority: Dec 13, 2005Filed: Dec 12, 2006Published: Nov 13, 2008
Est. expiryDec 13, 2025(expired)· nominal 20-yr term from priority
Inventors:Pierre Vandepapeliere
A61P 31/04A61P 37/04A61P 43/00A61P 31/22A61P 31/18A61P 31/16A61P 31/12A61P 31/20A61P 35/00A61P 37/00A61P 33/06A61P 15/00A61K 2039/5258A61K 2039/57A61K 2039/55577A61K 39/39A61K 2039/6068C12N 2730/10134A61K 39/092C12N 2710/16134C12N 2710/16171A61K 2039/55555C12N 2760/16171A61K 2039/6037C12N 2710/20071A61K 2039/55505C12N 2710/16771A61K 2039/545A61K 2039/55572A61K 2039/55A61K 39/015C12N 2760/16134C12N 2710/10134A61K 39/102C12N 2760/16234C12N 2760/20034A61K 39/145A61K 39/12C12N 2760/16271A61K 2039/70C12N 2710/16734A61K 39/1045Y02A50/30A61K 39/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An immunogenic composition in a dose volume suitable for human use comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 μg.

Claims

exact text as granted — not AI-modified
1 .- 91 . (canceled) 
     
     
         92 . An immunogenic composition in a dose volume suitable for human use comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of  Quillaja Saponaria  Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 μg. 
     
     
         93 . An immunogenic composition as claimed in  claim 92 , wherein said dose volume suitable for human use is between 0.5 and 1.5 ml. 
     
     
         94 . An immunogenic composition as claimed in  claim 93  wherein said dose volume is 0.5 ml. 
     
     
         95 . An immunogenic composition as claimed in  claim 93  wherein said dose volume is 0.7 ml. 
     
     
         96 . An immunogenic composition as claimed in  claim 93  wherein said dose volume is 1.0 ml. 
     
     
         97 . An adjuvant composition in a volume suitable for use in a human dose of an immunogenic composition comprising between 1 and 30 μg of a lipopolysaccharide and between 1 and 30 μg of an immunologically active saponin fraction presented in the form of a liposome. 
     
     
         98 . An adjuvant composition according to  claim 97  wherein said human dose suitable volume is 250 μl. 
     
     
         99 . An immunogenic composition according to  claim 92  wherein said adjuvant further comprises a sterol, wherein the ratio of saponin:sterol is from 1:1 to 1:100 w/w. 
     
     
         100 . An immunogenic composition according to  claim 99  wherein the ratio of saponin:sterol is from 1:1 to 1:10 w/w. 
     
     
         101 . An immunogenic composition according to  claim 99  wherein the ratio of saponin:sterol is from 1:1 to 1:5 w/w. 
     
     
         102 . An immunogenic composition according to  claim 92  wherein said immunologically active saponin fraction is QS21. 
     
     
         103 . An immunogenic composition according to  claim 99  wherein said sterol is cholesterol. 
     
     
         104 . An immunogenic composition according to  claim 92  wherein said lipopolysaccharide is a lipid A derivative. 
     
     
         105 . An immunogenic composition according to  claim 104  wherein said lipid A derivative is 3D-MPL. 
     
     
         106 . An immunogenic composition according to  claim 92  wherein said lipopolysaccharide and said immunologically active saponin fraction are present in the adjuvant composition at the same amount. 
     
     
         107 . An immunogenic composition according to  claim 106  wherein the ratio of QS21:3D-MPL is 1:1. 
     
     
         108 . An immunogenic composition according to  claim 92  wherein said lipopolysaccharide is present at an amount of 1-30 μg. 
     
     
         109 . An immunogenic composition according to  claim 108  wherein said lipopolysaccharide is present at an amount of 25 μg. 
     
     
         110 . An immunogenic composition according to  claim 108  wherein said lipopolysaccharide is present at an amount of 1-15 μg. 
     
     
         111 . An immunogenic composition according to  claim 110  wherein said lipopolysaccharide is present at an amount of 10 μg. 
     
     
         112 . An immunogenic composition according to  claim 110  wherein said lipopolysaccharide is present at an amount of 5 μg. 
     
     
         113 . An immunogenic composition according to  claim 92  wherein said saponin is present at an amount of 1-25 μg. 
     
     
         114 . An immunogenic composition according to  claim 113  wherein said saponin is present at an amount of 25 μg. 
     
     
         115 . An immunogenic composition according to  claim 113  wherein said saponin is present at an amount of 1-10 μg. 
     
     
         116 . An immunogenic composition according to  claim 115  wherein said saponin is present at an amount of 10 μg. 
     
     
         117 . An immunogenic composition according to  claim 115  wherein said saponin is present at an amount of 5 μg. 
     
     
         118 . An immunogenic composition according to  claim 92  wherein said antigen or antigenic preparation is derived from varicella zoster virus (VZV). 
     
     
         119 . An immunogenic composition according to  claim 92  wherein said antigen or antigenic preparation is derived from  Streptococcus pneumoniae.    
     
     
         120 . An immunogenic composition according to  claim 92  wherein said antigen or antigenic preparation is derived from Cytomegalovirus (CMV). 
     
     
         121 . An immunogenic composition according to  claim 92  wherein said antigen or antigenic preparation is derived from  Plasmodium falciparum.    
     
     
         122 . An immunogenic composition according to  claim 92  wherein said antigen or antigenic preparation is derived from influenza virus. 
     
     
         123 . An immunogenic composition according to  claim 92  wherein said antigen or antigenic preparation is derived from human papillomavirus (HPV).

Join the waitlist — get patent alerts

Track US2008279926A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.